Sponsored by Epicur Pharma® and Bova Group
*Please note: this recording is not approved for CE credits
This discussion provides US clinicians with the most up-to-date information on treatment and monitoring protocols for FIP that are being routinely utilized in Australia, the UK and Japan. This webinar aims to bring a very practical focus to ensure general practitioners feel confident to start readily treating these cases.
Dr. Sally Coggins graduated from The University of Sydney, Australia in 2007 and has been a feline-only clinician since 2010. She attained memberships in feline medicine with the ANZCVS in 2012, was a director at The Cat Clinic Melbourne, an examiner with the ANZCVS, and tutors for the Centre for Veterinary Education. Since 2020, Sally has been completing a PhD investigating antiviral therapies for FIP, where she conducted a national prospective study utilizing remdesivir and GS-441524; characterized the in vitro and in vivo pharmacokinetics of remdesivir in cats with FIP; co-authored a retrospective collaborative study assessing treatment outcomes of 307 cats treated with remdesivir and GS-441524 and has ongoing research collaboration with the US, UK, Germany and New Zealand. Sally also continues to practice clinically one day a week at Evervet in Melbourne, Australia.
2:15 Bova introduction & FIP background
7:07 GS-441524 drug details & ordering info
10:14 Legality of compounded GS-441524 in the US
14:18 Recap of key antivirals
17:36 Expected response rates
19:27 Current treatment protocols for GS-441524 & remdesivir
33:30 Things to avoid with remdesivir & GS-441524
35:52 Recommended monitoring & expected response to therapy
39:16 Suboptimal response to therapy &
50:23 How to decide which treatment option is best
56:03 Common FAQs
1:06:43 Live Q&A
We have a full library of webinars and other resources to help you continue learning about the topics important to you, your practice, and your patients!